FORMULATION AND EVALUATION OF STABILIZED EPROSARTAN NANOSUSPENSION

  • MODALA SANTHOSH RAJA ACHARYA NAGARJUNA UNIVERSITY
  • Dr.K.Venkataramana

Abstract

ABSTRACT:


Objectives: The objective of the current study is to enhance the solubility of Eprosartan mesylate a BCS Class II drug by employing nanoprecipitation technique.


Methods: Polymeric nanoparticles of Eprosartan mesylate were prepared by precipitation technique with various polymers like PVP K30, HPMC K15M, and Eudragit L100 in various ratios. The incompatibility issues which may arise between the drug and polymers are tested by differential scanning calorimetry (DSC). The formed nanosuspensions were evaluated for various parameters like particle size, zeta potential, drug content and dissolution testing.


Results: Among all the nanosuspension formulations, E12 formulation prepared with Eudragit L 100 showed better evaluation characteristics. SEM and DSC analysis showed no major interactions with the excipients. The maximum drug release was showed at 12h. The formulation E12 showed the particle size of 81.5 ± 5.5nm and zeta potential of -55.1mv.


Conclusion: Nano-precipitation method improved the dissolution as well as bioavailability of Eprosartan mesylate nanosuspension.


Key words: Bioavailability, Dissolution, Nanoprecipitation, Eprosartan mesylate, Eudragit.

Keywords: Bioavailability, Dissolution, Nanoprecipitation, Eprosartan mesylate, Eudragit.

Author Biography

Dr.K.Venkataramana

Principal,

A.S.N College of Pharmacy,

Burripalem Road, Tenali

Guntur, Andhrapradesh

References

1. Ramaiyan D, Vijaya Ratna J. Nanosuspensions technology in drug delivery – A review. Int J of Pharmacy Review & Research. 2012; 2 (1): 46-52.
2. Murthy RSR. In Vitro Evaluation of NPDDS. In: Yashwant Pathak, Deepak Thassu, editors. Drug Delivery Nanoparticles Formulation and Characterization. London: Informa Health Care; 2009. p.156-168.
3. Vishal RP, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. Journal of Advanced Pharmaceutical Technology & Research. 2011; 2 (2): 81-87.
4. Barrett E. Rabinow. Nanosuspensions in drug delivery. Nat Rev. 2004; 3: 785-796.
5. Muller RH, Dingler A, Schneppe T, Gohla S. Large-Scale Production of Solid Lipid Nanoparticles (SLN) and Nanosuspensions (DissoCubes). In: Donald L. Wise, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker; 2000. p. 359-375.
6. Amidon GL, Lennarnas H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutical Classification: The correlation of invitro product dissolution and invivo Bioavailability. Pharmaceutical Research. 1995; 12 (3): 413-420.
7. Muddana EB Rao, Suryakanta Swain, Chinam N Patra, Shakti P Mund. Formulation Design, Optimization and Characterization of Eprosartan Mesylate Nanoparticles. Nanoscience & Nanotechnology-Asia. 2018; 8 (1): 130-143.
8. Upasana Yadav, Nuzhat Husain, Qamar Rehman. Formulation of nanoparticles of Eprosartan mesylate for the better drug delivery by improving solubility. Asian Journal of Pharmaceutical and Clinical Research.2018;11(10): 260-263
9. Prachi Shekhawat, Milind Bagul, Diptee Edwankar, Varsha Pokharkar. Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder. European Journal of Pharmaceutical Sciences.2019; 132: 72-85.
10. Prachi Shekhawat, Varsha Pokharkar. Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment. Int J of Pharmaceutics. 2019;567:118415
11. Sabitri Bindhani, Snehamayee Mohapatra, Rajat Ku. Kar, Utkalika Mahapatra. Preparation of self micro emulsifying drug delivery system (SMEDDS) of poorly soluble drug Eprosartan mesylate and its in vitro evaluation. International journal of research in Pharmaceutical sciences. 2019; 10(4): 3304-3314.
12. Pankaj Dangre, Ritu Gilhotra, Shashikant Dhole. Formulation and statistical optimization of self-microemulsifying drug delivery system of Eprosartan mesylate for improvement of oral bioavailability. Drug Deliv and Transl Res. 2016; 6: 610–62.
13. Pankaj Vijay Dangre, Mangesh Dinanath Godbole, Priyanka Vijay Ingale, Debarshi Kar Mahapatra. Improved Dissolution and Bioavailability of Eprosartan Mesylate Formulated as Solid Dispersions using Conventional Methods. Ind J of Pharm Edu and Res. 2016; 50(3): 209-217.
14. Pradeep Kumar M, Chandrasekhar KB. (2017). Formulation and invitro and invivo characterisation of Nifedipine stabilized nanosuspensions by nanoprecipitation method. Int J of Res in Pharm Sci. 2017; 8 (4): 759-766.
15. Higuchi T. Mechanism of Sustained- Action Medication, Theoretical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices. J of Pharm Sci. 1963; 52 (12): 1145-1149.
16. John Pugh. Kinetics. In: M.E Aulton, KMG Taylor, editors. Aulton’s Pharmaceutics, The Design and Manufacture of Medicines. 4th ed. Edinburgh: Churchill Livingstone; 2013. p. 115-125.
17. Patrick J Sinko. Micromeritics. In: Patrick J Sinko, editor. Martin's Physical Pharmacy and Pharmaceutical Sciences. 6th ed. Philadelphia: Lippincott Williams and Wilkins. 2011; p. 442-468.
Statistics
7 Views | Downloads
How to Cite
MODALA SANTHOSH RAJA, & K.Venkataramana. (2020). FORMULATION AND EVALUATION OF STABILIZED EPROSARTAN NANOSUSPENSION. International Journal of Applied Pharmaceutics, 12(6). Retrieved from https://innovareacademics.in/journals/index.php/ijap/article/view/39123
Section
Original Article(s)